Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
|Videos|March 14, 2011
Dr. Alter Discusses Research at JTCC
Author(s)Robert S. Alter, MD
Dr. Robert Alter on Current Research at John Theurer Cancer Center
Advertisement
Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, discusses research taking place at the John Theurer Cancer Center, in the spring of 2011.
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5